Clinical Cancer Research Meeting Calendar AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 59, January 1, 2007. doi: 10.1158/1078-0432.CCR-06-1559
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishida, Y.
Right arrow Articles by Myoui, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishida, Y.
Right arrow Articles by Myoui, A.

Human Cancer Biology

Parthenolide, a Natural Inhibitor of Nuclear Factor-{kappa}B, Inhibits Lung Colonization of Murine Osteosarcoma Cells

Yuki Kishida1,2, Hideki Yoshikawa2 and Akira Myoui2,3

Authors' Affiliations: 1 Departments of Kampo Medicine and 2 Orthopaedics, Osaka University Graduate School of Medicine; and 3 Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan

Requests for reprints: Akira Myoui, Department of Orthopaedics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-3552; Fax: 81-6-6879-3559; E-mail: myoi{at}hp-mctr.med.osaka-u.ac.jp.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Purpose: The transcription factor nuclear factor-{kappa}B (NF-{kappa}B) regulates the expression of several genes important for tumor metastasis and is constitutively active in the highly metastatic murine osteosarcoma cell line LM8. Parthenolide, a sesquiterpene lactone, was reported to inhibit the DNA binding of NF-{kappa}B. The purpose of this study is to investigate the usefulness of parthenolide as target for antimetastatic therapies.

Experimental Design: We examined the effect of parthenolide on metastasis-associated phenotypes in vitro and in murine experimental lung metastasis models by s.c. and i.v. inoculation of LM8 cells.

Results: We found that parthenolide strongly induced apoptosis and inhibited cell proliferation and the expression of vascular endothelial growth factor in vitro. In the in vivo metastasis models, parthenolide treatment suppressed lung metastasis when treatment was initiated concurrently with s.c. or i.v. inoculation of tumor cells, whereas lung metastasis was not reduced when parthenolide was given after the homing of tumor cells. The growth of s.c. tumors that developed at the inoculation site was not suppressed by parthenolide. We also found that the genetic inhibition of NF-{kappa}B activity by expressing mutant I{kappa}B{alpha} suppressed lung metastasis in vivo but not s.c. tumor growth. This supports our notion that the metastasis-preventing effect of parthenolide is mediated at least in part by inhibition of NF-{kappa}B activity.

Conclusions: These findings suggested that NF-{kappa}B is a potential molecular target for designing specific prophylactic interventions against distant metastasis and that parthenolide is a hopeful candidate for an antimetastatic drug.

Osteosarcoma is the most common primary bone malignancy affecting children and young adults. The biggest difficulty with osteosarcoma is its high propensity for pulmonary metastasis. Patients with extremity lesions in whom lung metastases are detected at the time of diagnosis have a very poor prognosis. Modern multidisciplinary therapy has improved their outlook; however, up to half of the patients with osteosarcoma are still not cured. Thus, clarification of the molecular mechanism of pulmonary metastasis of osteosarcoma and introduction of a new intervention method are still needed (1).

Previously, we showed that LM8, a highly metastatic subclone of the Dunn murine osteosarcoma cell line, overexpressed valosin-containing protein (also known as p97) and exhibited increased nuclear factor-{kappa}B (NF-{kappa}B) activity (2). The transfection of valosin-containing protein in Dunn osteosarcoma cells could activate NF-{kappa}B and its metastatic potential. We also reported that the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase, which were regulated by NF-{kappa}B, was up-regulated in LM8 and in Dunn cells transfected with valosin-containing protein compared with original Dunn cells (3). These findings suggested that therapy against NF-{kappa}B activity is a prime target and has the potential to improve the prognosis of osteosarcoma.

NF-{kappa}B is an inducible dimeric transcription factor that belongs to the Rel/NF-{kappa}B family of transcription factors. NF-{kappa}B consists of two major polypeptides, p50 and p65 (4). In resting cells, NF-{kappa}B is sequestered in the cytoplasm by I{kappa}B proteins. Stimulus-mediated phosphorylation and subsequent proteolytic degradation of I{kappa}B allows the release and nuclear translocation of NF-{kappa}B, where it transactivates several target genes (5).

NF-{kappa}B plays a key role in the malignant behavior of tumors. It has been shown to regulate a whole cadre of genes important for angiogenesis, invasion, and metastasis (6–8). Studies of cell lines in vitro have shown that NF-{kappa}B is constitutively activated in many malignancies (9, 10). In addition, some investigators have shown that inhibition of NF-{kappa}B by insertion of mutated I{kappa}B into cancer cell lines causes decreased tumor growth and metastasis in vivo (11–14).

Parthenolide is one of the main sesquiterpene lactones responsible for the bioactivities of feverfew, a traditional folk remedy that has been used for various inflammatory conditions, such as rheumatoid arthritis, fever, and migraine (15, 16). Several studies have proposed that the effect of parthenolide is due to its ability to inhibit NF-{kappa}B activation. In addition, parthenolide was also reported to have microtubule-interfering properties (17) that induce apoptotic cell death by multiple pathways, including oxidative stress, endoplasmic reticulum stress, intracellular thiol depletion, caspase activation, and mitochondrial dysfunction (18, 19); inhibit 5-lipoxygenase and cyclooxygenase (20); and sensitize cancer cells to chemotherapeutic drugs, such as paclitaxel and CPT11 (21). Despite its potential as an anticancer drug, few studies have clarified the effect of parthenolide on metastasis (22) or the role of antitumor activities in the course of metastasis in vivo. We showed that parthenolide suppressed lung metastasis in LM8, a highly metastatic murine osteosarcoma cell line, by interference with tumor cell integration in lung tissue.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Cell culture. The cloned murine osteosarcoma cell line LM8, which shows a high metastatic incidence to the lung after s.c. inoculation into the back of mice, was cultured in DMEM containing 10% fetal bovine serum (Life Technologies, Gaithersburg, MD) in an air incubator with 5% CO2 at 37°C. In some cultures, parthenolide (Sigma Chemical, St. Louis, MO) was added at final concentrations of 0.2 to 200 µg/mL.

Animals. C3H male mice, ages 5 weeks, were purchased from Japan Oriental Yeast Co., Ltd. (Tokyo, Japan). All mice were housed under specific pathogen-free conditions with a 12-h light and dark cycle. The housing care rules and experimental protocol were approved by the Animal Care and Use Committee of Osaka University.

Electrophoretic mobility shift assay. Nuclear extracts of cells were prepared with the NE-PER nuclear extraction reagent (Pierce Biotechnology, Rockford, IL). Biotin end-labeled double-stranded oligonucleotides 5'-AGTTGAGGGGACTTTCCCAGGC-biotin-3' and 5'-TCAACTCCCCTGAAAGGGTCCG-biotin-3' were purchased from Invitrogen (Carlsbad, CA). The binding reactions contained 7.5 µg nuclear extract protein, buffer [10 mmol/L Tris (pH 7.5), 50 mmol/L KCl, 5 mmol/L MgCl2, 1 mmol/L DTT, 0.05% NP40, 2.5% glycerol], 1 µg poly(deoxyinosinic-deoxycytidylic acid), and 2 nmol/L biotin-labeled DNA. The reactions were incubated at room temperature for 20 min. The reactions were electrophoresed on a 10% precast Tris-borate-EDTA gel at 100 V for 1 h in 100 mmol/L Tris-borate-EDTA buffer and transferred to a nylon membrane. The biotin-labeled DNA was detected with a LightShift chemiluminescent electrophoretic mobility shift assay (EMSA) kit (Pierce Biotechnology). We repeated the assay for four times.

Luciferase assays. LM8 cells seeded in 24-well plates were transfected with pNF-{kappa}B-Luc (firefly luciferase driven by a TATA box with five NF-{kappa}B sites in the enhancer element; Stratagene, La Jolla, CA) by jetPEI (Polyplus Transfection, Biopark, France). Normalization of transfection efficiency was done by cotransfection with pRL-TK (Promega, Madison, WI) that contained cDNA encoding Renilla luciferase. Luciferase activities were quantified at 24 h using the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's instructions. We did the assay for four times.

Western blotting. LM8 cells in a 10-cm dish were starved with serum-free DMEM and incubated with various concentrations (0, 0.2, 2, 20, and 200 µg/mL) of parthenolide for 48 h. Ten-fold concentrated conditioned media were subjected to electrophoresis on a 12% SDS-polyacrylamide gel. Proteins were transferred to nitrocellulose filters. The membrane was incubated with rabbit polyclonal anti-mouse VEGF antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by horseradish peroxidase–conjugated secondary antibody (Santa Cruz Biotechnology). Visualization was done using Amersham enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ) according to the manufacturer's instructions. We repeated this assay thrice.

Invasion assay. Invasiveness into the reconstituted basement membrane Matrigel (Becton Dickinson, Franklin Lakes, NJ) was assayed. Cells were added into the upper compartment of a Transwell cell culture chamber and incubated with or without different concentrations of parthenolide. Fetal bovine serum at a final concentration of 10% (v/v) in culture medium was used as chemoattractant in the lower chamber. After 22 h of incubation, cells remaining on the upper surface of the membrane were removed with a cotton swab. Cells that invaded through the Matrigel-precoated membrane filter were fixed, stained by Giemsa, and then counted under a microscope. We repeated the assay for four times.

Flow cytometric analysis of apoptosis and the cell cycle. The effect of parthenolide on the cell cycle of LM8 cells was investigated by flow cytometric analysis of cells stained with propidium iodide (Sigma Chemical). Briefly, cells were trypsinized, washed in PBS, and fixed in 70% ethanol overnight at 4°C until used. Fixed cells were incubated with 1 mg/mL RNase (Sigma Chemical) for 60 min at 37°C. Then, 0.25 mg/mL propidium iodide was added for 15 min at 4°C in the dark. We acquired 10,000 cells using FACSCalibur (Becton Dickinson). Data were analyzed using ModFitLT 3.0 software (Becton Dickinson). These experiments were repeated for four times.

Spontaneous metastasis model. C3H male mice, ages 5 weeks, were used to estimate the in vivo metastatic potential to the lung. Tumor cells (1 x 105) were suspended in 200 µL DMEM and inoculated s.c. into the back of mice. To investigate whether parthenolide prevents tumorigenesis and lung metastasis in vivo, we developed two experimental protocols. In the prophylactic treatment model, in which parthenolide administration was initiated from the time of tumor cell inoculation, six groups of mice were used in the experiment. The first group (n = 8) was injected i.p. with a vehicle (PBS) every day. The other experimental groups (n = 4-14) received injections of parthenolide dissolved in distilled water at a dosage of 0.01, 0.1, 1, or 100 µg/kg or 1 mg/kg daily. In the therapeutic treatment model, treatment was started from day 17 after the onset of microscopic lung metastasis, confirmed in a preliminary experiment. The control group (n = 5) was injected i.p. with a vehicle (PBS), and the experimental groups received parthenolide at a dosage of 100 µg/kg (n = 4) or 1 mg/kg (n = 4) daily. All mice were killed on day 25, and primary tumors and lungs were collected for biochemical and histologic studies. We evaluated the volume of the primary tumor by measuring the three dimensions of the excised tumor.

Tail vein injection model. A total of 2 x 105 cells of LM8 was then resuspended in 200 µL PBS and injected into the tail vein of C3H male mice. Mice were divided into three groups and the first group (n = 7) was injected with a vehicle (PBS) every day. The second group (n = 7) received parthenolide at a dosage of 1 mg/kg daily, starting immediately after LM8 cell injection. The third (n = 7) group received the same dose of parthenolide every day starting from 48 h after cell injection. Seventeen days after cell injection, the mice were killed and the lungs were removed.

Histologic and immunohistochemical analyses. The tumors derived from implanted LM8 and the lungs were removed, fixed in 10% formalin, embedded in paraffin, and then cut into 4-µm sections. They were stained with H&E and the lungs were evaluated microscopically to confirm the presence of pulmonary metastasis. The proportional area of lung metastasis (the sum of the areas of lung metastasis/area of entire lung tissue) was calculated in lung sections with the largest tissue area. Immunohistochemistry was done using the streptavidin-peroxidase method with Histofine SAB-PO kits and an aminoethylcarbazole substrate kit (Nichirei, Tokyo, Japan) according to the manufacturer's protocol. Tissue sections were deparaffinized, hydrated in PBS, and incubated in 3% H2O2 in methanol for 20 min at room temperature to block endogenous peroxidase activity. After being washed in PBS, the sections were preincubated with 10% normal serum from the same species as the secondary antibody (to minimize background staining) for 20 min at room temperature and then incubated with an anti-p65 polyclonal antibody (Santa Cruz Biotechnology) or an anti-VEGF polyclonal antibody (Santa Cruz Biotechnology) overnight at 4°C. After washing in PBS, the sections were incubated with secondary antibody for 20 min at room temperature, then incubated with peroxidase-conjugated streptavidin for 20 min at room temperature, and washed in PBS. Finally, visualization was done using aminoethylcarbazole as a substrate. As a control for immunostaining, normal serum from the same species as the primary antibodies was used instead of the primary antibodies.

Tumor cell homing in lung tissue. LM8 cells were additionally labeled by the membrane dye PKH using the fluorescence cell linker kit PKH26 (Sigma Chemical). Then, a total of 2 x 105 cells was suspended in 200 µL PBS and injected into the tail vein of C3H mice (n = 15). Parthenolide treatment at a dosage of 1 mg/kg daily was initiated concomitantly with injection of LM8. At 4 (n = 5), 24 (n = 5), and 48 h (n = 5) after cell injection, the mice were killed and the lungs were removed. The lungs were then homogenized in PBS. The fluorescence of the released PKH26 was measured at 551 nm. Data were expressed as units of PKH26 released (1 unit = 1 unit of fluorescence at 551 nm) per milligram of protein in each culture. The assay was done in triplicate.

Stable transfection of LM8 cells with I{kappa}B{alpha}M and control vector. LM8 cells were transfected with pCMV-I{kappa}B{alpha}M expression vector or control pCMV-I{kappa}B{alpha} vector (Clontech, Mountain View, CA) using jetPEI. The I{kappa}B{alpha}M gene differed from wild-type I{kappa}B{alpha} by serine-to-alanine mutations at residues 32 and 36. These mutations protected I{kappa}B{alpha} from ubiquitination and proteasome-mediated proteolysis. Thus, the product of pCMV-I{kappa}B{alpha}M blocked NF-{kappa}B activation in a dominant-negative fashion. Cells were selected with standard medium containing G418 (Life Technologies). Two clones (M7 and M9) that overexpress I{kappa}B{alpha}M and a control clone (CTL), which was transfected with control pCMV-I{kappa}B{alpha} vector, were selected.

Statistical analysis. Data are presented as mean ± SD. Groups were compared by one-way ANOVA and individual groups were compared using the Mann-Whitney U test for unpaired analysis. Differences between treatment groups were considered significant at P < 0.05.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
NF-{kappa}B DNA binding and transcription activity of NF-{kappa}B was inhibited by parthenolide. To assess the influence of parthenolide on NF-{kappa}B signaling in LM8 cells, EMSAs for NF-{kappa}B were done. We added parthenolide or vehicle to subconfluent LM8 cell cultures for 1 h and nuclear protein was extracted. As shown in Fig. 1A , NF-{kappa}B DNA binding was inhibited by parthenolide dose dependently. Additionally, we determined the effect of parthenolide on the transactivational activity of NF-{kappa}B in LM8 cells by promoter reporter assay. As shown in Fig. 1B, NF-{kappa}B transcriptional activity was inhibited by parthenolide in a dose-dependent manner. The NF-{kappa}B activity in the cells incubated with high-dose parthenolide (200 µg/mL) was 10-fold lower than the control.


Figure 1
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. In vitro effect of parthenolide on murine osteosarcoma cell line LM8. A, EMSA for NF-{kappa}B. LM8 cells were pretreated with parthenolide for 1 h. Nuclear extracts were subjected to EMSA. Parthenolide inhibits the DNA binding of NF-{kappa}B. B, transcriptional activity of NF-{kappa}B. A Luciferase reporter assay for NF-{kappa}B transcriptional activity was done as described in Materials and Methods. NF-{kappa}B transcriptional activity was inhibited by parthenolide dose dependently. Representative data from four different experiments. C, VEGF secretion was decreased by parthenolide. Conditioned medium of LM8 cell cultures treated by parthenolide was analyzed for VEGF expression by Western blotting. D, parthenolide reduced the invasiveness of LM8. Invasiveness was determined using a Matrigel-precoated cell culture insert (n = 4). Representative data from three different experiments. Columns, mean; bars, SD. *, P < 0.05 to controls without parthenolide (ANOVA).

 
VEGF expression was inhibited by parthenolide. When cultured in serum-free medium, LM8 cells released VEGF in culture medium as determined by Western blotting. Parthenolide treatment inhibited the secretion of VEGF in a dose-dependent manner (Fig. 1C).

Invasive potential was inhibited by parthenolide. Invasive potential of LM8 cells after incubating with parthenolide was determined using the Matrigel invasion assay. Figure 1D shows that tumor cell invasion was decreased by parthenolide in a dose-dependent manner.

Parthenolide inhibited cell growth and induced apoptosis in LM8 cell culture. We determined the effect of parthenolide on the cell cycle of LM8 cells using FACS analysis. Parthenolide treatment reduced the growth fraction (S + G2-M) and increased the apoptosis fraction (sub-G1) at 4, 12, and 24 h. At 48 h, parthenolide treatment abolished the G1 peak and no cells seemed to be viable under the microscope (Fig. 2 ).


Figure 2
View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Cell cycle analysis in LM8 cells treated with or without parthenolide at 4, 12, 24, and 48 h. Representative data from four different experiments. Results are expressed as a percentage of the cells in each fraction. *, P < 0.05 from untreated control at each time point. ND, not determined.

 
Parthenolide had a distinct effect on lung metastasis but no effect on tumorigenesis in the prophylactic treatment model. We evaluated the effect of parthenolide on tumors in vivo using a murine LM8 model of metastasis. After s.c. inoculation of tumor cells, all mice developed large primary tumors at the injection site. In the prophylactic treatment model, the primary tumors treated with parthenolide of >1 µg/kg/d tended to be smaller than the vehicle-treated control tumors but the differences were not statistically significant (Fig. 3A ). However, we observed that pulmonary metastatic nodules were dramatically suppressed by parthenolide. There were significant differences in the proportional area of lung metastasis between vehicle-treated and parthenolide-treated mice (Fig. 3B-F). Especially, treatment with parthenolide of >1 µg/kg/d effectively suppressed lung metastasis. Immunohistchemical analysis showed strong p65 expression in the lung metastatic nodules of the untreated mice. However, metastatic tumors treated with parthenolide of 1 mg/kg/d were negative for p65 immunolocalization. Immunohistochemistry also showed that VEGF expression of metastatic lung tumors and surrounding lung tissue was clearly suppressed by parthenolide treatment compared with untreated metastatic tumors of similar size (Fig. 3G-N).


Figure 3
View larger version (67K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. The effect of parthenolide on tumor metastasis in the prophylactic model. LM8 cells (1 x 105) were injected s.c. into the back of mice. The mice were treated with i.p. injection of parthenolide or vehicle (PBS) starting from the day of tumor cell inoculation. A, the primary tumors treated by parthenolide tended to be smaller than the controls but no statistically significant difference was found. B, pulmonary metastatic nodules were dramatically suppressed by parthenolide. n = 4-14 from three different experiments. Columns, mean; bars, SD. *, P < 0.05 from PBS control. C to F, microphotographs of the lungs treated by PBS (C) and by parthenolide at a dosage of 1 µg/kg/d (D), 100 µg/kg/d (E), and 1 mg/kg/d (F). Bar, 1 mm. Magnification, x40. Immunohistochemical analyses of the tumor nodules in lung tissue treated with PBS (G-J) and with parthenolide at a dosage of 1 mg/kg/d (K-N). The expression of p65 was suppressed in parthenolide-treated mice (L) compared with control mice (H). The expression of VEGF was also suppressed in the parthenolide-treated mice (M) compared with control mice (I). An intrinsic positive control of VEGF was vascular endothelial wall. G and K, H&E staining. Arrowheads, blood vessels; arrows, tumor nodules. J and N, negative controls without primary antibodies. Bar, 100 µm. Magnification, x100.

 
Parthenolide had no effect on lung metastasis or tumorigenesis in the therapeutic treatment model. Next, we did the experiment to determine whether parthenolide can decrease pulmonary lung nodules after the development of lung metastasis. The primary tumor volumes and the proportional area of lung metastasis showed no significant difference between vehicle-treated and parthenolide-treated mice (Fig. 4 ).


Figure 4
View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Parthenolide did not suppress tumor metastasis in the therapeutic treatment model. The mice were treated with parthenolide or vehicle (PBS) initiating from day 17 after the onset of lung metastasis. No statistically significant difference was observed in the volume of the primary tumors (A) or the proportional ratio of lung metastasis (B) between vehicle-treated and parthenolide-treated mice. Control group, n = 5; treatment groups, n = 4. Columns, mean; bars, SD. H&E stainings of the lung with PBS (C), 100 µg/kg/d parthenolide (D), and 1 mg/kg/d parthenolide (E). Magnification, x40.

 
Parthenolide interferes with early events of tumor cell colonization in lung. To clarify where parthenolide works during the multistep metastatic process, we tested its effect in a lung metastasis model by tail vein injection. The lung metastasis of mice that received parthenolide concomitantly with tumor cell inoculation was significantly reduced compared with other groups (Fig. 5A-D ). In the mice treated with parthenolide starting from 48 h after the injection of tumor cells, the lung metastasis was not suppressed (Fig. 5B and D), suggesting that parthenolide inhibited metastasis not by working on the steps before extravasation but by working on early events of lung colonization that occur within 48 h after cell intravasation. Then, we examined the effect of parthenolide on the homing of tumor cells to lung tissue. After 4 or 24 h, there was no significant difference in the fluorescence of labeled LM8 cells in the lung between the control group and the parthenolide-treated group. However, the fluorescence in the mice treated with parthenolide gradually decreased with time and, at 48 h, it was significantly lower than that in mice that were treated with PBS of 48 h (Fig. 5E).


Figure 5
View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. The effect of parthenolide on lung metastasis in a tail vein injection model. The H&E staining of lung tissue of the mice that received PBS (A), parthenolide starting from 48 h after cell injection (B), and parthenolide concomitantly with the injection of LM8 (C). The lung metastasis of mice that received parthenolide concomitantly with the injection of tumor cells was significantly reduced compared with other groups (n = 7; D). LM8 cells were labeled by the membrane dye PKH and injected into the tail vein. Parthenolide treatment at a dosage of 1 mg/kg daily was initiated concomitantly injection of cells. At 4, 24, and 48 h after cell injection, the fluorescence of the released PKH in lung tissue was measured. At 4 and 24 h, there was no significant difference in the fluorescence of labeled cells in the lung between the control group and the parthenolide-treated group. However, the fluorescence treated with parthenolide gradually decreased with time and was significantly lower than that treated with PBS at 48 h (n = 5; E). Points, mean; bars, SD. *, P < 0.05 to PBS control.

 
Blocking NF-{kappa}B activation inhibited VEGF expression and lung metastasis in vivo. We established LM8 cell clones that were stably transfected with an I{kappa}B{alpha} mutant expression vector pCMV-I{kappa}B{alpha}M. Two clones (M7 and M9) were selected. Nuclear proteins from transfectants and wild-type cells were analyzed by EMSA for NF-{kappa}B binding activity. DNA binding of NF-{kappa}B was inhibited in both mutant clones (Fig. 6A ). Consistent with these results, the NF-{kappa}B-luciferase reporter assay (n = 4) showed that the transcription activity of NF-{kappa}B was significantly reduced in those clones compared with control clone, CTL (Fig. 6B).


Figure 6
View larger version (36K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Suppression of NF-{kappa}B activity by the overexpressing mutant I{kappa}B{alpha} reduced VEGF secretion and blocked lung metastasis. An I{kappa}B{alpha}M construct was transfected to LM8 cells and two clones (M7 and M9) were selected according to the activity of NF-{kappa}B for in vitro and in vivo studies. EMSA of NF-{kappa}B DNA binding in M7 and M9 and in CTL, a clone that was transfected with control vector (A), and transcriptional activity of NF-{kappa}B by luciferase reporter assay (n = 4; B). Columns, mean; bars, SD. *, P < 0.05 to CTL without tumor necrosis factor-{alpha} (TNF-{alpha}). #, P < 0.01 to CTL with tumor necrosis factor-{alpha}. These clones were subjected to the spontaneous metastasis model for their metastatic potential. No statistically significant difference was observed in the volume of the primary tumors (C); however, the proportional area of lung metastasis in the mice inoculated with I{kappa}B{alpha}M clones was significantly smaller than that with the control clone (n = 6; D). Columns, mean; bars, SD. *, P < 0.05 to CTL. Representative microphotographs of the lungs of the mice injected with M7 (E), M9 (F), and CTL (G) cells. H&E staining. Magnification, x40.

 
Next, we tested the metastatic potential of those clones in vivo using a spontaneous metastasis model to determine whether selective inhibition of NF-{kappa}B suppresses lung metastasis. As shown in Fig. 6C, the primary tumor volumes were not statistically different between the mice implanted with I{kappa}B{alpha}M clones and the mice implanted with CTL (n = 6). However, we found that pulmonary metastatic nodules in the mice implanted with the clones overexpressing I{kappa}B{alpha} mutant were dramatically suppressed, especially in the M7 clone with the lowest NF-{kappa}B activity. There were significant differences in the proportional area of metastasis between the mice with CTL and the mice with M7 or M9 (Fig. 6D-G).


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Suppression of various genes that are involved in tumor cell invasion and angiogenesis on blockade of NF-{kappa}B activity has been reported in cancer cells (12, 23–27). Although previous studies claimed the involvement of several cytokines under the regulation of NF-{kappa}B, such as interleukin-8, tumor necrosis factor-{alpha}, and VEGF, in the regulatory mechanisms (12, 22–25, 28, 29), little has been known when and how NF-{kappa}B is implicated during the multistep cascade of events in the development of metastasis. In addition, although parthenolide, an inhibitor of NF-{kappa}B, has also shown antimetastatic activity in vitro (21, 30), there have been few reports about its in vivo antimetastatic activity or its mode of action (22). Our in vivo experiments showed the following: (a) lung metastasis was suppressed when parthenolide was given starting concurrently with s.c. inoculation of tumor cells into the back of mice or i.v. administration of tumor cells; (b) lung metastasis was not reduced when parthenolide was given after homing of the tumor cells; (c) parthenolide had little effect on the size of the primary tumor; and (d) inhibiting NF-{kappa}B activity by overexpressing I{kappa}B{alpha}M suppressed lung metastasis but not tumorigenesis. These data suggest that parthenolide, perhaps by inhibiting NF-{kappa}B activity for the most part, prevented lung metastasis mainly by working on early events in lung colonization involving interactions between tumor cells arrested in the capillary bed and the microenvironment at the target site not just by suppressing tumor cell proliferation.

It is now recognized that resistance to cell death, particularly apoptotic cell death, is an important aspect of metastatic progression (31). During the multistep metastatic cascade, it is believed that tumor cells withstand severe proapoptotic pressures from host cell cytokines and growth factors (32–34). Constitutively activated NF-{kappa}B-mediated transcription has been well documented in association with the induction of antiapoptotic genes and the ability of cancer cells to evade apoptosis induced by various stimuli (35). Parthenolide has been reported to induce apoptosis effectively (19, 36, 37). Our data also showed that inhibition of NF-{kappa}B activity by parthenolide resulted in strong induction of LM8 cell apoptosis in vitro. Recent in vivo videomicroscopic studies showed that most tumor cells arrested in microvasculature at the metastatic site successfully extravasated and survived as solitary cells for 3 days but only a few percentage of the cells started to replicate to form micrometastases (38). In our study, an experimental metastasis model by i.v. inoculation of fluorescence-labeled tumor cells showed that parthenolide did not affect the tumor cell arrest in lung vasculature at 4 h. However, fluorescence derived from tumor cells in lung tissue gradually decreased over time with parthenolide treatment with a significant difference at 48 h, suggesting that parthenolide, at least in part, induced tumor cell death before the cells can form multicellular micrometastatic foci.

NF-{kappa}B is one of the most important upstream regulators of VEGF, a major angiogenic factor that induces endothelial cell proliferation. In our data, parthenolide clearly decreased VEGF secretion by LM8 cells in vitro. Moreover, in the spontaneous metastasis model, it suppressed the expression of immunoreacting VEGF at lung metastatic foci where intracellular accumulation of NF-{kappa}B was suppressed as well. These observations suggest that one of the mechanisms by which parthenolide inhibits lung metastasis is the suppression of VEGF expression via NF-{kappa}B inactivation. A recent study showed that disrupting VEGF signaling leading to vascular leakage by the pretreatment with pharmacologic inhibitors of VEGF could alleviate lung metastasis. It showed that the inhibitor could get the beneficial effect within the first days after tumor cell inoculation, when solitary tumor cells are beginning to extravasate and proliferate (39). These observations were consistent with our results in the i.v. tumor cell inoculation model, which revealed failure in the blockade of metastasis with parthenolide treatment starting from 48 h after cell inoculation. This supports our notion that the metastasis-preventing effect of parthenolide is mediated at least in part by inhibition of VEGF secretion.

Although the inhibition of NF-{kappa}B activity by expressing I{kappa}B{alpha}M has been shown to suppress metastasis in a variety of tumors, the reports differ about the effect on the growth of primary tumors (11, 12, 14, 25). Our study showed that parthenolide effectively blocked the development of lung metastasis of osteosarcoma but did not block the proliferation of the primary site tumor or established lung metastases. Despite its suppressive effect on the cell cycle in vitro, its poor effect on established tumors in vivo might spoil the importance of proliferation suppression among the putative mechanisms of metastasis inhibition by parthenolide. However, the pharmacodynamic properties of parthenolide are still under investigation (40) and there remains the possibility that parthenolide is not to be delivered in high enough concentrations to established tumors when given systemically.

Several antitumor studies on the inhibition of NF-{kappa}B activity in vivo used a gene therapy, including an I{kappa}B mutant. Parthenolide is currently used commonly as a food supplement for the treatment of migraines and reportedly has no severe side effects compared with the placebo group; therefore, it may be easier and more efficient than gene therapy in vivo (15). Mutation of p53 is a common genetic alteration in cancers that is closely associated with resistance to systemic therapy. A recent study revealed that one possible pathway through which mutants of p53 may induce loss of drug sensitivity is via the NF-{kappa}B pathway (41). Parthenolide directly blocks NF-{kappa}B activity regardless of p53 status and also induces apoptosis via the c-Jun NH2-terminal kinase pathway independent of NF-{kappa}B and p53. Thus, parthenolide could be expected to have an effect on tumors with the p53 mutation that poorly respond to anticancer drugs (30).

In conclusion, we showed that parthenolide, a sesquiterpene lactone derived from natural herbs, inhibited lung metastasis in a spontaneous metastasis model and an i.v. metastasis model using the highly metastatic murine osteosarcoma cell line LM8. Although extensive clinical studies are needed to clarify whether this is also the case in human patients with cancers, our results suggest that NF-{kappa}B is a potential molecular target for designing specific prophylactic interventions against distant metastasis.


   Footnotes
 
Grant support: Ministry of Education, Culture, Sports, Science and Technology, Japan grants 17390417 and 18591631 (H. Yoshikawa and A. Myoui) and the Ministry of Health, Labor, and Welfare, Japan (Cancer Research grant 14-17; A. Myoui).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/28/06; revised 10/ 3/06; accepted 10/13/06.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Whelan JS. Osteosarcoma. Eur J Cancer 1997;33:1611–8; discussion 8–9.[CrossRef][Medline]
  2. Asai T, Tomita Y, Nakatsuka S, et al. VCP (p97) regulates NF{kappa}B signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93:296–304.[CrossRef]
  3. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998;76:418–22.[CrossRef][Medline]
  4. Thanos D, Maniatis T. NF-{kappa}B: a lesson in family values. Cell 1995;80:529–32.[CrossRef][Medline]
  5. Baldwin AS, Jr. The NF-{kappa}B and I{kappa}B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–83.[CrossRef][Medline]
  6. Hansen SK, Nerlov C, Zabel U, et al. A novel complex between the p65 subunit of NF-{kappa}B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 1992;11:205–13.[Medline]
  7. Yokoo T, Kitamura M. Dual regulation of IL-1ß-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-{kappa}B and AP-1. Am J Physiol 1996;270:F123–30.
  8. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor {alpha}-dependent angiogenesis. Mol Cell Biol 1997;17:4015–23.[Abstract]
  9. Meyskens FL, Jr., Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-{kappa}B in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 1999;5:1197–202.[Abstract/Free Full Text]
  10. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-{kappa}B during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629–39.[Abstract]
  11. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-{kappa}B{alpha} of nuclear factor-{kappa}B in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468–74.[Abstract/Free Full Text]
  12. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor {kappa}B in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346–54.[Abstract/Free Full Text]
  13. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-{kappa}B activity. Cytokines Cell Mol Ther 2000;6:9–17.[CrossRef][Medline]
  14. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-{kappa}B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188–97.[CrossRef][Medline]
  15. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189–92.[Medline]
  16. Schinella GR, Giner RM, Recio MC, Mordujovich de Buschiazzo P, Rios JL, Manez S. Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 1998;50:1069–74.[Medline]
  17. Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact 2004;149:165–73.[CrossRef][Medline]
  18. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004;208:143–53.[CrossRef][Medline]
  19. Wen J, You KR, Lee SY, Song CH, Kim DG. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 2002;277:38954–64.[Abstract/Free Full Text]
  20. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313–20.[CrossRef][Medline]
  21. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-{kappa}B is enhanced by I{kappa}B{alpha} super-repressor and parthenolide. Oncogene 2000;19:4159–69.[CrossRef][Medline]
  22. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005;4:1004–12.[Abstract/Free Full Text]
  23. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor {kappa}B. Cancer Res 2000;60:6557–62.[Abstract/Free Full Text]
  24. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-{kappa}B signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334–9.[Abstract/Free Full Text]
  25. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-{kappa}B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573–81.[Abstract/Free Full Text]
  26. Ko HM, Seo KH, Han SJ, et al. Nuclear factor {kappa}B dependency of platelet-activating factor-induced angiogenesis. Cancer Res 2002;62:1809–14.[Abstract/Free Full Text]
  27. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-{kappa}B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511–23.[Abstract/Free Full Text]
  28. Huber MA, Azoitei N, Baumann B, et al. NF-{kappa}B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569–81.[CrossRef][Medline]
  29. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NF{kappa}B signaling cascade. Mol Cancer Res 2003;1:701–6.[Abstract/Free Full Text]
  30. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330–44.[CrossRef][Medline]
  31. Malaguarnera L. Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 2004;23:367–87.[CrossRef][Medline]
  32. Evan GI, Vousden KH. Proliferation, cell cycle, and apoptosis in cancer. Nature 2001;411:342–8.[CrossRef][Medline]
  33. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31–101.[Medline]
  34. Yousefi S, Conus S, Simon HU. Cross-talk between death and survival pathways. Cell Death Differ 2003;10:861–3.[CrossRef][Medline]
  35. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-{kappa}B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680–3.[Abstract/Free Full Text]
  36. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res 2005;65:6312–20.[Abstract/Free Full Text]
  37. Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Rho/Rhotekin-mediated NF-{kappa}B activation confers resistance to apoptosis. Oncogene 2004;23:8731–42.[CrossRef][Medline]
  38. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865–73.[Abstract/Free Full Text]
  39. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223–9.[Abstract/Free Full Text]
  40. Curry EA III, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22:299–305.[CrossRef][Medline]
  41. Scian MJ, Stagliano KE, Anderson MA, et al. Tumor-derived p53 mutants induce NF-{kappa}B2 gene expression. Mol Cell Biol 2005;25:10097–110.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishida, Y.
Right arrow Articles by Myoui, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishida, Y.
Right arrow Articles by Myoui, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online